Question 1

What are the potential benefits and risks of participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors clinical trial (NCT06451497). Contact the study team or your healthcare provider for specific answers.

Question 2

How does ZM008 compare to my current treatment options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors clinical trial (NCT06451497). Contact the study team or your healthcare provider for specific answers.

Question 3

What kind of monitoring and tests will I undergo during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors clinical trial (NCT06451497). Contact the study team or your healthcare provider for specific answers.

Question 4

How long will I need to participate, and how often will I need to visit the clinic?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors clinical trial (NCT06451497). Contact the study team or your healthcare provider for specific answers.

Question 5

What should I do if I experience side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors clinical trial (NCT06451497). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any costs associated with participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors clinical trial (NCT06451497). Contact the study team or your healthcare provider for specific answers.

What this study is about